Letter: cytokeratin-18 as a biomarker of hepatocellular carcinoma regression after transarterial chemoembolization
Aliment Pharmacol Ther
.
2017 Jan;45(1):183-184.
doi: 10.1111/apt.13820.
Authors
Z-H He
1
,
W-R He
2
,
L-L Wu
3
,
C Zhao
4
,
N-F Peng
4
,
B-K Ahir
5
,
C-Y Lu
1
Affiliations
1
Department of Hepatobiliary Surgery, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, China.
2
Department of Gastroenterology, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
3
School of Pharmacy, Guangxi Medical University, Nanning, China.
4
Department of Hepatobiliary surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
5
Section of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
PMID:
27910148
DOI:
10.1111/apt.13820
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Biomarkers
Carcinoma, Hepatocellular*
Chemoembolization, Therapeutic
Humans
Keratin-18*
Liver Neoplasms
Substances
Biomarkers
Keratin-18